Physician profile
Roya Ghafouri
NPI 1790943355
$2,086.48
in general payments reported to CMS, 2019-2025
11 companies · $62.93 in 2025
The $62.93 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $90.08 · 2021: $82.07 · 2022: $409 · 2023: $250 · 2024: $409 · 2025: $62.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $721.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $726.41 | 2019-2023 | Dysport |
| Allergan, INC. | $499.99 | 2019-2022 | |
| Revance Therapeutics, INC. | $292.87 | 2024-2025 | Daxxify |
| Horizon Therapeutics Plc | $158.57 | 2021-2023 | Tepezza |
| Amgen INC. | $124.86 | 2024-2025 | Tepezza |
| Arcutis Biotherapeutics, INC. | $121.69 | 2023 | |
| Abbvie INC. | $82.79 | 2023-2025 | |
| Rxsight INC | $25.13 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Akorn, INC. | $19.32 | 2020 | |
| Alcon Vision LLC | $15.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Ghafouri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.